Inspection and Enforcement 
Drs. Kennedy (OSTP) and Elder raised the question of whether this provision 
should be more specific and leave less to the discretion of the Secretary. 
Mr. Riseberg, NIH legal advisor, stated that this language is patterned 
after the CDC Clincial Laboratory Improvement Act and that the details are 
later to be specified by the regulatory agency. Dr. Elder promised to 
provide further language for the committee to consider. 
Patents 
Dr. Ancker-Johnson explained the nature and purpose of the accelerated 
handling order issued on January 13th and emphasized that this order could 
serve an important function as an interim measure to obtain adherence to 
the NIH guidelines. Each representative received a copy of the order and 
Dr. Fredrickson asked that each review the order for further discussion at 
the next committee meeting. 
Discussion then turned to the protection of trade secrets. Dr. Ancker-Johnson 
offered the opinion that neither Section 4 of the FOI Act nor the Disclosure 
of Information section of the Bill of Particulars affords adequate protection. 
Mr. Riseberg explained that the purpose of this section in the Bill of 
Particulars is to provide an appeal mechanism for the submitter and that 
it is similar to the language used in TOSCA. Mr. McGarity, EPA, stated 
that this language has worked well for his agency. 
[ 259 ] 
